Author

Natasha Muzengi

Observed names: N Muzengi, N. Muzengi

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Inserm, Public Health England, National Institute for Health and Care Research, University of Oxford, Public Health Scotland, National Records of Scotland, Nepal Health Research Council, Hôpital Raymond-Poincaré, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia, Infection et inflammation, Canadian Critical Care Trials Group

OpenAlex ID: A5063019765

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

2021 · Hesham Abdelhady, Marwa Abdelrazik, et al. · JAMA · 210

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 136

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

2021 · Yaseen M. Arabi, Anthony C. Gordon, et al. · Intensive Care Medicine · 99

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

2023 · Simin Florescu, Delia Stanciu, et al. · JAMA · 63

Intravenous Vitamin C for Patients Hospitalized With COVID-19

2023 · The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Simin Florescu, et al. · JAMA · 53

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2024 · RECOVERY Collaborative Group, Peter Sandercock, et al. · Nature Communications · 11

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Works count: 12

Citation count: 2,293

H-index: 11

I10-index: 11